TG Therapeutics, Inc. (TGTX) Analysts See $-0.55 EPS

July 13, 2018 - By Nellie Rakes

Investors sentiment decreased to 1.46 in Q1 2018. Its down 0.54, from 2 in 2017Q4. It worsened, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported.
Gam Holdings Ag invested in 98,600 shares. 195,524 are owned by D E Shaw. Ameritas Investment Prtnrs, a Nebraska-based fund reported 4,260 shares. Aqr Cap Mgmt Ltd Com holds 0% or 47,267 shares in its portfolio. Moreover, Ubs Asset Mgmt Americas has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 950,934 shares. Exane Derivatives invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Moreover, Macquarie Limited has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Hollencrest Mgmt accumulated 12,000 shares. 62 were accumulated by Hanson Mcclain. Franklin Resource holds 0.02% or 2.41M shares. 59,940 are held by Alliancebernstein Limited Partnership. Quantbot Limited Partnership owns 3,822 shares for 0% of their portfolio. The Ohio-based Stratos Wealth Partners has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). California State Teachers Retirement System has invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Tiaa Cref Inv Management Lc reported 122,466 shares stake.

Since June 14, 2018, it had 0 buys, and 2 selling transactions for $960,508 activity. Another trade for 25,071 shares valued at $337,205 was made by KENNEDY WILLIAM JAMES on Thursday, June 14.

Analysts expect TG Therapeutics, Inc. (NASDAQ:TGTX) to report $-0.55 EPS on August, 8.They anticipate $0.10 EPS change or 22.22 % from last quarter’s $-0.45 EPS. After having $-0.59 EPS previously, TG Therapeutics, Inc.’s analysts see -6.78 % EPS growth. The stock increased 0.37% or $0.05 during the last trading session, reaching $13.45. About 623,196 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since July 14, 2017 and is uptrending. It has outperformed by 2.14% the S&P500.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 3 analysts covering TG Therapeutics (NASDAQ:TGTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 6 analyst reports since January 17, 2018 according to SRatingsIntel. As per Thursday, April 19, the company rating was maintained by Raymond James. As per Friday, March 9, the company rating was maintained by FBR Capital. FBR Capital maintained the stock with “Buy” rating in Wednesday, January 17 report. FBR Capital maintained the stock with “Buy” rating in Friday, February 2 report. FBR Capital maintained it with “Buy” rating and $2500 target in Monday, June 4 report. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Wednesday, March 21 by H.C. Wainwright.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.04 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

More recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Seekingalpha.com which released: “Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3” on June 20, 2018. Also Seekingalpha.com published the news titled: “Trillium up 13% premarket” on June 21, 2018. Seekingalpha.com‘s news article titled: “TG Therapeutics: An Immunology Powerhouse” with publication date: June 14, 2018 was also an interesting one.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.